OR WAIT 15 SECS
Across the pharmaceutical industry, advances in digital technology play a key role in driving the efficiency of the drug development process, particularly for clinical trials.
Across the pharmaceutical industry, advances in digital technology play a key role in driving the efficiency of the drug development process, particularly for clinical trials. As data continues to migrate from paper to electronic format, electronic signatures can contribute to productive and cost-effective clinical trials, saving tens of thousands of dollars in operational costs and drastically reducing the high costs of administrative delays. As described below, Sarah Cannon Research Institute provides an ideal example of the compelling benefits, in which they reduced the time it takes to get physicians’ signatures by up to a staggering 94%.
Forrester predicts the use of e-signatures to skyrocket over the next two years, and within the clinical trial process, the opportunities to leverage e-signature technologies are abundant. E-signatures present substantial opportunities to lower operational costs associated with the huge volume of paper used throughout a clinical trial. Of greater importance, however, e-signatures can drastically reduce the time required to sign mission-critical documents, which otherwise could hold up a trial’s activity for days or weeks on end, thereby resulting in tremendous financial benefits.
As noted above, the Sarah Cannon Research Institute (SCRI) implemented e-signatures to meet the challenge of rising clinical trial costs and ever-burdening paperwork. Running approximately 500 clinical trials a year, the organization’s volume of document processing, shipping and storage was immense.
SCRI’s e-signature program was designed to expedite gathering physician signatures on clinical trial documents, encompassing a network of more than 1,000 investigators dispersed globally. This e-signature ability saved SCRI $250,000 in printing and delivery costs in the first year, but even more important, it saved time. Previously, it took between 19 and 58 days to get a document signed. With e-signatures, it took just three to four days – a 94% improvement.
The need for speed in clinical trials
Such successes are critical in today’s environment. A Manhattan Institute report states that in 1975, the pharmaceuticals industry spent the equivalent of $100 million (adjusted to 2012 dollars) for research and development on one drug. By 1987, that figure tripled to $300 million, and by 2005, the number more than quadrupled to $1.3 billion. Today, of course, the figure is even more staggering – double what it was 10 years ago. Tufts Center for the Study of Drug Development reports it costs close to $2.6 billion to develop a drug today.
Unfortunately, the high volume of paper-based processes in a clinical trial contributes to inevitable delays in signing and processing. “The average new drug application submission, which includes data from all clinical trials related to that application, uses between two and six million pages of paper. For a visual picture, organizations often require the use of long-haul vans or tractor trailers for transport,” said Mollie Shields Uehling, CEO of SAFE-BioPharma Association. “For each piece of paper, someone must scan and process the document. When done millions of times, it can accumulate lost time significantly. Even more, the data in paper documents - in physical or scanned form - isn’t easily searchable, which can further contribute to administrative delay.” When e-signature technology is deployed through the cloud, physicians and other signers can access and sign documents anywhere there is an Internet connection and on virtually any mobile device.
For clinical research organizations to build a successful platform, e-signature adopters should first begin with the right digital infrastructure to support the heightened needs of clinical research workflows. Because clinical trial paperwork differs significantly from that of the average business using electronic signatures, a rudimentary e-signature solution could undermine compliance.
For instance, most e-signatures used in the United States are generally compliant with the federal
and the Uniform Electronic Transactions Act (UETA), which outline the basic legal framework for legally acceptable e-signatures in the U.S. These two pieces of legislation are relatively broad, however, and do not adequately address the enhanced security, long-term validity and reliable identity authentication necessary in the life sciences industry.
One kind of e-signature, called an independent e-signature (also referred to as a digital signature), exceeds the mandates of ESIGN and UETA by directly and permanently embedding an e-signature’s cryptographic information (or legal evidence) into the signed document. Other types of e-signatures, those that are dependent on a vendor, simply link the signature back to a vendor’s server.
This distinction is fundamental. Because the legal evidence is embedded into a PDF and not reliant on a vendor’s proprietary technology and permanent storage of the document, independent e-signature technologies can be validated, even without an Internet connection, and can live exclusively on a user’s server – not a vendor’s - for greater control.
Such characteristics of independent e-signatures conform to industry-specific regulations, which must also be considered when sourcing e-signature technology. Most notably, this includes compliance with HIPAA and FDA 21 CFR Part 11.
FDA 21 CFR Part 11 requires heightened levels of security controls, such as detailed audit trails, tamper evidence and multi-factor authentication, which are all components of independent e-signatures. HIPAA’s language does not specify appropriate use of e-signatures, but the spirit of the law clearly mandates the staunch defense of patients’ protected health information. Keeping direct ownership and control of documents via independent e-signatures is a critical factor in protecting any PHI found in electronically signed documents.
Further, HIPAA and FDA 21 CFR Part 11 guidelines alone are not enough to make e-signatures legally permissible in other parts of the world. For instance, independent e-signatures that utilize a unique digital certificate, or identity, are the only e-signatures permitted by the European Medicines Agency.
Effectively launching e-signatures for clinical trials
Though the underlying e-signature technology required for clinical trials is indeed advanced, it’s relatively simple to capture an e-signature. To optimize an e-signature program’s effectiveness, however, administrators ought to consider the following during implementation:
Clinical trials play an essential role in shaping modern-day medicine. The stakes are exceedingly high, even down to the paperwork. Given the right technology, solution provider and internal commitment, e-signatures provide a vehicle for efficiency and expediency that can drastically improve one of the last legs of a therapy’s journey to market.
Pem Guerry is Executive Vice President at SIGNiX
Related Content:Online Extras